ArticleTranslational psychiatry2022
Cytokine profile in drug-naïve panic disorder patients.
Article in Translational psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07444879 (Investigation of IL-33, sST2, and C-Reactive Protein in Panic Disorder), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigation of IL-33, sST2, and C-Reactive Protein in Panic Disorder: A Cross-Sectional Case-Control Study
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Minocycline attenuates panicogenic responses in a COTranslational psychiatry · 2026Trial
- IL-37 and Neuroimmune Mechanisms Relevant to Depressive and Anxiety Disorders: A Scoping Review.International journal of molecular sciences · 2026Article
- Altered serum interleukin-4 and monocyte chemoattractant protein-3 levels are associated with generalized anxiety disorder: a case-control study.Experimental biology and medicine (Maywood, N.J.) · 2026Article
- Interleukin-40 and Oxidative Stress in Patients With Generalized Anxiety Disorder.Psychiatry investigation · 2025Article
- Social anxiety disorder and antibodies against glial cells in the cerebrospinal fluid.Brain, behavior, & immunity - health · 2025Article
- Exploring the Potential Targets and Protective Agents in Mercury-Induced Anxiety Disorders Using Network Toxicology, Network Pharmacology, and Molecular Docking.Iranian journal of child neurology · 2025Review
- Altered serum interleukin-17A and interleukin-23A levels may be associated with the pathophysiology and development of generalized anxiety disorder.Scientific reports · 2024Article
- Association of interleukin-2 and interleukin-10 with the pathophysiology and development of generalized anxiety disorder: a case-control study.BMC psychiatry · 2024Article
- Exploring the role of interleukin-1β and interleukin-6 in the pathophysiology of obsessive-compulsive disorder.PloS one · 2024Article
- Pilot study of genome-wide DNA methylation and gene expression for treatment response to escitalopram in panic disorder.World journal of psychiatry · 2023Article
- Inflammatory and mental health sequelae of COVID-19.Comprehensive psychoneuroendocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although accumulating evidence suggests that inflammatory processes play a role in the pathophysiology of mental disorders, few studies have investigated this matter in panic disorder (PD). Furthermore, no studies to date have evaluated cytokine levels in drug-naïve patients with PD. Therefore, little is known about the presence of inflammation at the onset of this disorder. The aim of the present study was to determine the levels of the proinflammatory interleukins IL-1B and IL-2R and the anti-inflammatory cytokine IL-10 in drug-naïve PD patients. Analysis of serum chemokine levels revealed increased proinflammatory activity in the early phase of PD through increased IL-2R and IL-1B levels and a decrease in IL-10 levels in drug-naïve PD patients compared to matched healthy controls. Neurotransmitters and neurocircuits that are targets of inflammatory responses are discussed, followed by an examination of brain-immune interactions as risk factors for PD. This study is the first to identify a proinflammatory cytokine response in drug-naïve PD subjects. These findings indicate that treatments targeting proinflammatory markers may ameliorate anxiety symptoms in PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.